Management of Conjugated Hyperbilirubinemia

Initial Assessment

The American Gastroenterological Association recommends determining whether hyperbilirubinemia is predominantly conjugated or unconjugated to narrow down potential causes 2
Bilirubin in urine indicates conjugated (direct) hyperbilirubinemia, as only conjugated bilirubin is water-soluble and can be excreted in urine 1
Normal liver enzymes with bilirubinuria suggests a potential biliary obstruction that may not be severe enough to cause enzyme elevation, or could indicate early stages of a hepatobiliary disorder 1

Ultrasound of the abdomen is the most appropriate initial imaging study, with high positive predictive value (98%) for liver parenchymal disease and sensitivity ranges from 65-95% for liver parenchymal disease and 32-100% for biliary obstruction 1
The American College of Radiology recommends ultrasound as the first-line imaging study due to its non-invasive nature, ready availability, and cost-effectiveness 3, 1
Complete fractionated bilirubin levels should be checked to confirm conjugated hyperbilirubinemia 2
Liver enzyme elevation patterns, including ALT, AST, ALP, and GGT, should be evaluated, even if within normal range 1, 2

For CBD diameter >10mm, consider MRCP or ERCP even with normal liver enzymes, with MRCP preferred due to its non-invasive nature and high accuracy in diagnosing causes of mechanical CBD obstruction 3
If no biliary dilation is present, consider MRI/MRCP to exclude pathology that might be missed by ultrasound, or MDCT with contrast if MRI is contraindicated or unavailable 3
MDCT has sensitivity >90% for biliary obstruction and can determine both site and cause 3

Drug-induced liver injury should be considered, and all medications and supplements should be reviewed for potential hepatotoxicity 5, 2
If immune checkpoint inhibitor therapy is being administered, monitor closely as hepatitis is a potential immune-related adverse event 5
For patients with NASH and elevated baseline ALT, different thresholds for liver enzyme monitoring apply (≥2× baseline or ≥300 U/L) 6

If initial workup is inconclusive, consider liver biopsy to evaluate for intrahepatic causes 1, 2
Liver tests should be monitored periodically while investigating the underlying cause, with more frequent monitoring (every 3-7 days) recommended for moderate-severe elevations or symptomatic patients 2